Products - Metastases | Topic | NICE

Showing 139 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2024
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 July 2024
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 June 2024
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (IPG786)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 May 2024
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 February 2024
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 December 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2023
Spinal metastases and metastatic spinal cord compression (NG234)
Product type:
Guidance
Programme:
NICE guideline
Published:
6 September 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 June 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 May 2023
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
26 April 2023
Published:
26 July 2010
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 April 2023
Radiofrequency ablation for palliation of painful spinal metastases (IPG758)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
5 April 2023
Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases (IPG759)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
5 April 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 May 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 March 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 February 2022
Microwave ablation for primary or metastatic cancer in the lung (IPG716)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
2 February 2022
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) (TA750)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 December 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2021
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2021
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 September 2021
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 September 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 June 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 April 2021
Published:
11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 April 2021
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
21 April 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Brain tumours (primary) and brain metastases in over 16s (NG99)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
29 January 2021
Published:
11 July 2018
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 January 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 October 2020
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 September 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Selective internal radiation therapy for unresectable colorectal metastases in the liver (IPG672)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
4 March 2020
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Padeliporfin for untreated localised prostate cancer (TA546)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 November 2018
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 August 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 July 2018
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 July 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 May 2018
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2018
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2017
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
25 September 2017
Published:
29 March 2017
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published:
25 November 2015
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2017
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
29 March 2017
Published:
14 December 2011
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
24 August 2016
Published:
25 May 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 April 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Microwave ablation for treating liver metastases (IPG553)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 April 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 February 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2015
Published:
12 December 2012
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 October 2014
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2014
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
14 August 2013
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
7 August 2013
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 March 2013
Irreversible electroporation for treating liver metastases (IPG445)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2013
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2013
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2013
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2012
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 October 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2012
Published:
24 January 2007
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2011
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2010
Cryotherapy for the treatment of liver metastases (IPG369)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
15 December 2010
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 November 2010
Published:
27 October 2004
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Radiofrequency ablation for colorectal liver metastases (IPG327)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2009
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2009
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2009
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2007
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2006
Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 June 2006
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2003
Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 January 2018
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
20 September 2017
OSNA for colon cancer staging (MIB77)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
24 August 2016
Spinal metastases and metastatic spinal cord compression (QS56)
Product type:
Quality standard
Last updated:
6 September 2023
Published:
27 February 2014
Brain tumours (primary) and brain metastases in over 16s (QS203)
Product type:
Quality standard
Published:
7 December 2021
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016